The board of directors of RemeGen Co., Ltd. announced that the Company has completed the Phase II clinical study for telitacicept (RC18, Brand Name: ®) to treat patients with IgA nephropathy (IgAN) in China and obtained the preliminary data readout. 44 patients were recruited in the Phase II clinical study. Preliminary result showed that the reduction of proteinuria level from the treatment groups was statistically higher than the baseline, when compared with the placebo group, the difference is statistically significant. In addition, analysis of several secondary endpoints further identified significant difference between the treatment group and the placebo group. The clinical data will be published in relevant international conferences or journals. The Company plans to launch further studies in both China and U.S.A. IgA nephropathy (IgAN) is an immune-complex-mediated glomerulonephritis characterized by hematuria, proteinuria, and variable rates of progressive renal failure. IgAN is the most common cause of primary kidney disease worldwide. According to Frost & Sullivan, the number of IgAN patients globally increased from 8.8 million in 2015 to 9.3 million in 2020 (including 2.2 million in China). The total number of IgAN patients globally is forecasted to reach 9.7 million by 2025 (including 2.3 million in China), and to 10.2 million by 2030 (including 2.4 million in China).